End Brain Cancer Initiative - the Chris Elliott Fund

Investigational product Immune12 is a proprietary complex biologic derived from specific marine-sourced ingredients.

A phase 2 clinical trial of Immune12 is currently recruiting glioblastoma (GBM) brain cancer patients in Australia (ANZCTR).

Request more information and pre-qualify with the End Brain Cancer Initiative: https://monkeylink.co/18c24b

During Gray May, also known as “National Brain Tumor Awareness Month,” we come together as a community to show our support for everyone who has been affected by brain tumors and brain cancer.

The End Brain Cancer Initiative is seeking to raise $50,000 to increase patient access to specialized care and treatments. Support EBCI now: https://monkeylink.co/724487

Your support makes it possible for us to continue our important work, including:

💚 FREE one-on-one patient/caregiver engagement when it is needed the most to help patients get IMMEDIATE ACCESS to specialists, treatments, devices, diagnostics, clinical trials.

💚 Critical patient education through extensive online resources, free patient education events, our global digital outreach program, and more.

💚 EBCI's advocacy initiatives which lead to more FDA-approved treatments and increased patient access.